Recent study in the Journal of Urology shows PredicineCARE urine-based liquid biopsy test provides non-invasive molecular profiling for patients with bladder cancer
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer.
Excerpt from the Press Release:
“This study demonstrates the clinical value of urine-based liquid biopsy testing to provide a non-invasive and highly accurate option to assess somatic alterations and to identify potential targeted therapies in patients with newly diagnosed urothelial bladder cancer,” said Dr. Shidong Jia, Founder
HAYWARD, Calif. (PRWEB) September 29, 2021
Predicine, Inc. announces results from a study demonstrating the concordance between tissue testing and analysis of urinary circulating tumor DNA (utDNA) while utilizing the PredicineCARE liquid biopsy NGS assay to detect somatic cancer variants in patients with urothelial bladder cancer (UBC).
The study published in the Journal of Urology evaluates the concordance between the “gold standard” of tumor tissue DNA (tDNA) with blood circulating tumor DNA (ctDNA) and urinary circulating tumor DNA (utDNA). The study is entitled “Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.” The study utilized PredicineCARE, a 152-gene next-generation sequencing assay that evaluates somatic cancer variants.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?